START-lungNCT07203053
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 15 versions: 14 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites reduced: 19 → 13 locations
- Notable Eligibility criteria expanded, about 51 words
- Secondary endpoints: details revised at 4 of 5 entries
- Site details revised at 3 of 19 sites
- Minor Site details revised at 1 of 19 sitesv13
- Minor Site details revised at 1 of 19 sitesv12
- Minor Site details revised at 1 of 19 sitesv11
Show 4 earlier versionsHide 4 earlier versions
- Minor Site details revised at 1 of 19 sitesv10
- Minor Site details revised at 1 of 19 sitesv9
- Minor Site details revised at 1 of 19 sitesv8
- Minor Site details revised at 2 of 19 sitesv7
- Notable Recruitment opened
- Start date changed from estimate of May 2026 to Apr 15, 2026
- Site details revised at 19 of 19 sites
- Minor Study sites: 1 to 19v4
- Minor Study sites: 0 to 1v3
- Minor Study title shortened, about 3 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Overall survival rate at 12 months (12-month OS)
Timeframe: OS is defined as the time from the date of enrolment until death from any cause. Assessed for approximately up to 41 months.
Secondary (5)
Objective response rate (ORR)
Duration of response (DoR)
Disease control rate (DCR)
Progression-free survival (PFS)
Incidence, nature, and severity of adverse events
Arms and interventions
TarlatamabExperimental
Drugs: Tarlatamab
Sites
13 sites in 5 countries
Switzerland 4, Italy 3, Spain 3, France 2, Greece 1